This page is hosted by the Gainesville UF Office of Clinical Research on behalf of the Office of Research Affairs, UF College of Medicine-Jacksonville.
Throughout the Coronavirus (COVID-19) crisis, the Office of Research Affairs at the University of Florida College of Medicine-Jacksonville is committed to maintaining research services and administration functions while also serving as a resource for COVID-19 related information and resources.
Each of these sections contain a variety of regularly updated UF and non-UF web links with related COVID-19 information and resources. If you have specific COVID-19 research related questions, please visit the Office of Research Affairs Portal to submit your request.
This section provides access to the grant announcements related to COVID-19.
This section is comprised of a variety of UF Jacksonville and Gainesville websites that together, offer a broad overview of the COVID-19 information UF is providing.
This section is comprised of a variety of UF Jacksonville and Gainesville websites that together, provide a broad overview of the COVID-19 research-related information UF is providing.
This section provides access to the Sponsor websites and updates as they relate to COVID-19.
This section provides a list of COVID-19 related research, studies, publications, awards, etc. involving UF Jacksonville employers and departments. As with the other sections, we will continuously update this section.
General UF information about COVID-19
- Access to the COVID-19 Website
- Frequently Asked Questions
- Human Resource Reminders
- Pregnant Health Care Workers and COVID-19
- Privacy Updates
- About COVID-19
- Information for Patients
- Information for Visitors, Vendors and Contractors
- Information for Employees
- Various RSS Feed
- Frequently Asked Questions
- Updates from the University of Florida
- COVID-19 Cases Update
UF Research Updates
- Sponsor Updates
- Sponsored Programs Related Telework Activities
- COVID-19 Grant Opportunities
- Archived Memos from Office of UF Research
- Animal Care
- Human Subjects Research and Clinical Trials
- Guidance from Federal Agencies
- Research Integrity
- Program Development and Funding Opportunities
- Urgent Competitive Revision to Existing NIH Grants and Cooperative Agreements (Urgent Supplement)
- Information for NIH Applicants and Recipients of NIH Funding Related to COVID-19
- NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options
- NIH has received emergency funding for COVID-19-related activities in two supplemental bills
- Institutional and Agency Responses to COVID-19
- Agency Guidance Specific to Federal Award Impact
- Institutional Guidance
- Additional Resources
- Frequently Asked Questions
- Grants and Funding Opportunities
- Listserv access for additional funding opportunities
- Provides a list of Open Requests for Application of Rapid-Response Translational Research Projects to Address COVID-19 Pandemic
Other Selected Funding Opportunities
- American Diabetes Association COVID-19 and Diabetes Research Award
- Bill and Melinda Gates Foundation: Statement from the Bill & Melinda Gates Foundation about today’s Coronavirus Global Response Summit
- Centers for Disease Control: Improving Clinical and Public Health Outcomes through National Partnerships to Prevent and Control Emerging and Re-Emerging Infectious Disease Threats
- Department of Defense (DoD): Newton Award for Transformative Ideas during the COVID-19 Pandemic
- Department of Defense (DoD): Peer Reviewed Medical Research Program (PRMRP) open to Emerging Viral Diseases and Respiratory Health with a focus on COVID-19
- Johnson&Johnson Nurses Innovate QuickFire Challenge in COVID-19 Patient Care
- Merck: Research Grant for Pandemic Preparedness
- National Institute of Health (NIH) National Allergy and Infectious Diseases (NIAID): Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R21 Clinical Trial Not Allowed)
- National Institute of Health (NIH) National Allergy and Infectious Diseases (NIAID): Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) (R01 Clinical Trial Not Allowed)
- National Institute of Health (NIH) Notice of Special Interest (NOSI)Data Driven Research on Coronavirus Disease 2019 (COVID-19) (R21)
- National Institute of Health (NIH) Point-of-Care Technology Research Network (POCTRN): Fast Track Program for COVID-19 Test Development and Distribution; Innovative Technologies to Increase U.S. Capacity for COVID-19 Testing
- Patient-Centered Outcomes Research Institute (PCORI): Engagement Award Special Cycle: Supporting Engagement in and Dissemination of PCOR/CER in the Context of COVID-19
- Patient-Centered Outcomes Research Institute (PCORI): COVID-19: Notice of Upcoming PCORI Funding Announcement (PFA)
- Pfizer: Pfizer – COVID-19 Competitive Grant Program
- Robert Wood Johnson Foundation: Emergency Response for the Health Care System – Innovation Challenge
- Robert Wood Johnson Foundation: Emergency Response for the General Public – Innovation Challenge
- Robert Wood Johnson Foundation: Supplemental Research on COVID-19 Response and Recovery
UF Jacksonville COVID-19 Active Research
PI: Mark L. Hudak, MD
Pregnant women are at risk for COVID-19 infection during the current pandemic. To date, information about the different routes (transplacental, perinatal, and postnatal) and risks of transmission of this disease to newborn infantsis anecdotal and not population-based. Given that SARS-CoV-2 is a respiratory virus, the risk of transplacental transmission might be presumed to be very low to absent. The risk of postnatal transmission is likely to be very high if the newborn is not immediately separated from the mother, and the severity of postnatally acquired disease in the newborn is unknown.The SONPM National Registry will provide population data on dyads of mothers who deliver who test positive for COVID-19 infection between 14 days before through 3 days after delivery, and their infants.
PI: Nizar Maraqa, MD
The HERO Registry allows health care workers across the country to share clinical and life experiences so organizers can better understand the perspectives and problems they face on the COVID-19 pandemic front lines. The registry seeks the participation of anyone who works in a setting where people receive health care.Health care workers can participate as much or as little as they like through surveys and clinical trial opportunities. Future studies will help improve understanding of COVID-19 and beyond, generating evidence to help keep health care workers safe and healthy.
To join the HERO Registry please click here
For additional information please contact Office of Research Affairs, UF College of Medicine Jacksonville